CRISPR Therapeutics Names Brendan Smith To Succeed Michael Tomsicek As CFO - Quick Facts

Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Thursday the appointment of Brendan Smith as Chief Financial Officer, effective today. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio.

Smith succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.

Prior to CRISPR Therapeutics, Smith was the CFO & Corporate Strategy of Translate Bio, a company that was recently acquired by Sanofi for $3.2B. Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy positions.

Previously, as a Partner at Boston Consulting Group, Smith led integrated biopharma client engagements that included planning and executing on R&D strategy, operations, business development and deal diligence. Prior to that, he was VP, Head of Business Operations for Worldwide R&D at Pfizer, where he led financial and headcount planning across discovery and development operations.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT